Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 12/20 | 0.41 |
| ▸ | HTR2A | P28223 | 9/20 | 0.41 |
| ▸ | HTR2B | P41595 | 6/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.36 |
| ▸ | EED | O75530 | 1/20 | 0.34 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.34 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL705701 | 1.00 | HTR2C (0.41) | HTR2CHTR2AHTR2BCYP1A1MTNR1A | |
| SCHEMBL436395 | 0.90 | HTR2C (0.38) | HTR2CHTR2AHTR2BCYP1A1MTNR1A | |
| SCHEMBL251263 | 0.90 | HTR2C (0.38) | HTR2CHTR2AHTR2BCYP1A1MTNR1A | |
| SCHEMBL9720820 | 0.85 | HTR2C (0.35) | HTR2CHTR2AHTR2BCYP1A1MTNR1A | |
| SCHEMBL1479650 | 0.85 | HTR2C (0.35) | HTR2CHTR2AHTR2BMTNR1AMTNR1B | |
| SCHEMBL401248 | 0.82 | TYR (0.42) | HTR2CCYP1A1 | |
| SCHEMBL11814414 | 0.82 | TYR (0.42) | HTR2CCYP1A1 | |
| SCHEMBL3427515 | 0.82 | TYR (0.42) | HTR2CCYP1A1 | |
| SCHEMBL11499668 | 0.78 | TYR (0.36) | HTR2CHTR2AHTR2BCYP1A1MTNR1A | |
| SCHEMBL249424 | 0.78 | TYR (0.36) | HTR2CHTR2AHTR2BCYP1A1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663183-B1 | SOLID PHARMACEUTICAL DOSAGE FORM COMPRISING RITONAVIR | ABBOTT LAB (US) | 2011-07-13 | — | — | EP | claimed |
| EP-2283844-A1 | A solid pharmaceutical dosage formulation comprising lopinavir | Abbott Laboratories (US) | 2011-02-16 | — | — | EP | claimed |
| US-20110015216-A1 | Solid Pharmaceutical Dosage Form | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | claimed |
| US-20110008430-A1 | Solid Pharmaceutical Dosage Form | ABBOTT LABORATORIES (US) | 2011-01-13 | — | — | US | claimed |
| US-7399731-B2 | Electrically conductive non-aqueous wellbore fluid | M-I L.L.C. (US) | 2008-07-15 | — | — | US | claimed |
| US-20220204968-A1 | LYSIS, BINDING AND/OR WASH REAGENT FOR ISOLATING AND/OR PURIFYING NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2022-06-30 | — | — | US | disclosed |
| US-20220002708-A1 | LYSIS, BINDING AND/OR WASH REAGENT FOR ISOLATING AND/OR PURIFYING NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2022-01-06 | — | — | US | disclosed |
| EP-2703466-B1 | WATER-REPELLENT AND OIL-REPELLENT AGENT COMPOUND, MANUFACTURING METHOD THEREFOR, AND ARTICLE | ASAHI GLASS CO LTD (JP) | 2018-07-11 | — | — | EP | disclosed |
| US-20170159042-A1 | LYSIS, BINDING AND/OR WASH REAGENT FOR ISOLATING AND/OR PURIFYING NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2017-06-08 | — | — | US | disclosed |
| US-20170159041-A1 | LYSIS, BINDING AND/OR WASH REAGENT FOR ISOLATING AND/OR PURIFYING NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2017-06-08 | — | — | US | disclosed |
| US-9617532-B2 | Lysis, binding and/or wash reagent for isolating and/or purifying nucleic acids | QIAGEN GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| EP-2537907-B1 | RELEASE AGENT COMPOSITION | ASAHI GLASS CO LTD (JP) | 2016-04-20 | — | — | EP | disclosed |
| US-20110076751-A1 | LYSIS, BINDING AND/OR WASH REAGENT FOR ISOLATING AND/OR PURIFYING NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2011-03-31 | — | — | US | disclosed |
| EP-2283844-A1 | A solid pharmaceutical dosage formulation comprising lopinavir | Abbott Laboratories (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20110015216-A1 | Solid Pharmaceutical Dosage Form | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110008430-A1 | Solid Pharmaceutical Dosage Form | ABBOTT LABORATORIES (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100129455-A1 | NANOPARTICLE-DISPERSED FINE GLASS BEADS HAVING A CAVITY THEREIN, AND METHOD OF PRODUCING THE SAME | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100021540-A1 | Tablets and Preparation Thereof | ABBOTT LABORATORIES (US) | 2010-01-28 | — | — | US | disclosed |
| US-7399731-B2 | Electrically conductive non-aqueous wellbore fluid | M-I L.L.C. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20030132033-A1 | Electrically conductive non-aqueous wellbore fluid | M-I L.L.C. | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100129455-A1 | NANOPARTICLE-DISPERSED FINE GLASS BEADS HAVING A CAVITY THEREIN, AND METHOD OF PRODUCING THE SAME | MSN, CD47, DNMT1 | HTR2C 4800/4885HTR2A 4220/4885HTR2B 4092/4885 |
| US-20100021540-A1 | Tablets and Preparation Thereof | GRN, EXOSC9, ALG3 | HTR2C 3793/4885HTR2A 2438/4885HTR2B 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.